After 8-year-old son dies, Northwest Indiana family urges vaccination against meningitis-causing bacteria
With that in mind, a grieving Northwest Indiana family wants to share a message about vaccinating children.
Lake Prairie Elementary School in Lowell, Indiana, will be chirping with activity for the first day of school soon. Liam Dahlberg will not be there to start fourth grade.
"He was one-of-a-kind," said Liam's still-tearful mom, Ashlee Dalhberg. "Anybody that knew him, described him as a walking angel on earth."
Liam is now an angel in heaven. His parents, Ashlee and Erik Dahlberg, want to share the tragedy that robbed them of their 8-year-old — they showed CBS News Chicago videos of Liam looking completely out-of-it in the emergency room.
"That Thursday turned his world upside down, and ours as well," said Erik Dahlberg.
The Thursday in question transpired in April of this year. After a normal day of school, Liam got off the bus and complained of a headache.
"We gave him ibuprofen, and he went outside and was playing with his friends for a while," said Erik Dahlberg. "Then he came back in and said he had a headache again."
The family from Lowell took Liam to a local hospital after he began hallucinating. He was quickly transferred to the Comer Children's Hospital at the University of Chicago.
"He had over 100,000 white blood cells in his spinal fluid," said Ashlee Dahlberg.
It was a sign that Liam's body was fighting a severe infection. That battle caused meningitis — meaning Liam's brain swelled.
"We were just trying to cheer him on, trying to pull him through — hoping for that slight miracle that he would come through," said Ashlee Dahlberg.
Liam died around 3 a.m. that Saturday — only 36 hours after getting off the bus with a headache.
"I just don't want anyone else to go through what we've gone through for something that is so preventable," said Ashlee Dahlberg.
Indeed, what happened to Liam is vaccine preventable. Dr. Allison Bartlett, a pediatric infectious disease expert at Comer, knows all about that.
"I'm really glad for people who have the courage to speak up and share their stories," Bartlett said.
Dr. Bartlett did not work personally on Liam's case, but her colleagues did. They noted in his hospital record, "We are suspicious for Haemophilus influenzae Type B," also known as HIB.
Haemophilus influenzae are a type of bacteria.
"There are years where there's not even 20 cases in the country," said Bartlett.
Disease caused by HIB decreased by 99% after vaccines were introduced in the late 1980s and early 1990s.
"How is HIB still out there? There is not much of it around, which is great," said Bartlett. "But it's not completely gone. And it's probably more likely present in someone who is not vaccinated."
Liam had all his shots. But about 20% of Lake County, Indiana kids are not vaccinated for HIB, according to state health data.
HIB immunization rates across the state dropped during the COVID-19 pandemic, and are still recovering.
"As levels of vaccinations surrounding them decrease, it increases the risk for the individual who happened to not respond to the vaccine," said Bartlett.
That was what happened to Liam. And with their son gone, the Dahlbergs will do anything to help their message.
"Please do the vaccinations," said Ashlee Dahlberg.
"If we can persuade one parent who is on the fence about vaccine or not vaccine, then it's all worth it," said Erik Dahlberg.
Indiana does not require the HIB vaccine, but recommends it to go to daycare or preschool. Illinois mandates the vaccine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Cardinal Health expands urology focus with $1.9bn Solaris Health deal
US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio
Yahoo
19 minutes ago
- Yahoo
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Entrepreneur
20 minutes ago
- Entrepreneur
What's Really Inside Your Supplements? This Founder Is Uncovering the Truth Behind the $180 Billion Industry
From creatine to NAD+, this company is uncovering the truth behind mislabeled, underdosed and overhyped products. Opinions expressed by Entrepreneur contributors are their own. I recently wrote about creatine and profiled Jeff Byers, co-founder of Momentous, for a reason: integrity matters. When it comes to what we put in our bodies, especially for entrepreneurs aiming to optimize energy, recovery and longevity, founders and consumers deserve transparency and truth. And yet, the supplement industry is booming with very little of either. We're in the middle of a health optimization gold rush. Creatine gummies, NAD+ capsules, sleep pills and brain-boosting stacks are everywhere. Scroll Instagram, walk into Erewhon or search Amazon, and you'll find thousands of options. The global supplement industry is growing fast and is expected to top $240 billion by 2028, yet many of these products do not contain what they claim to. You may be spending $30, $50 or $90 on a supplement and getting barely a trace of the active ingredient, or in some cases, nothing at all. Unlike pharmaceuticals, supplements don't require FDA approval before hitting the market. That creates a loophole where products can launch quickly, and claims, unless dangerously false, go largely unchecked. And it's not just obscure or small brands. Some of the top-selling supplements on Amazon are underdelivering, misleading or worse. That's where Steve Martocci and SuppCo come in. Martocci, best known for founding the music-tech platform Splice, is now on a mission to fix one of the most frustrating problems in wellness: a lack of transparency. SuppCo is a health tech startup that independently tests supplements and publishes public reports that give consumers one thing the industry often avoids: truth. CEO and Co-Founder, Martocci, struggled with his health for most of his life, reaching nearly 300 pounds despite playing three sports and training consistently. Martocci said to me, "Traditional medicine failed me. I remember being told my labs were on the 'low end of normal' and that nothing could be done. It was completely disheartening." After selling GroupMe to Skype, Martocci discovered functional medicine and began working with a doctor on a tailored supplement stack. He lost nearly 100 pounds over the next year and realized that even though supplements had become mainstream, there was no software actually to help people navigate this space. The supplement industry is a $180 billion market, yet it's filled with confusion, noise and a multitude of products that don't deliver what they promise. With SuppCo, Martocci is on a mission to transform how people discover, manage and optimize their supplement routines. Join top CEOs, founders and operators at the Level Up conference to unlock strategies for scaling your business, boosting revenue and building sustainable success. I was introduced to SuppCo's work through their recent Creatine Gummies Report. Creatine, which I personally take and have written about, is one of the most well-researched supplements for both brain and physical performance. But not all products are created equal. SuppCo tested five popular creatine gummy brands sold on Amazon. Only two passed. One contained less than 25% of the labeled amount. SuppCo recently published a report on NAD+ supplements, a trending ingredient in the longevity and cellular energy space, which tested nine products and was even more revealing. 4 passed (Double Wood, Rho Nutrition Liposomal, NatureBell and Thinbi), with Thinbi exceeding its claim at 103%. 5 failed, including Maripolio, which showed 0% of its claimed NAD+. Others tested at less than 3% of the listed amount on the label. NAD+ was the perfect follow-up to the creatine testing series because it represents everything confusing about the supplement space right now. Martocci explained that NAD+ is one of the fastest-rising compounds in longevity and biohacking, endorsed by scientists and influencers, but it's also one of the most confusing for consumers. Martocci said, "You can supplement with NAD+ itself or its precursors like NR and NMN, and most consumers don't understand the bioavailability differences between the three and that one of them is distinctly worse." When we see brands cutting corners on things we can measure, like certifications and testing transparency, they're usually cutting corners on things we can't see too, like what's actually in the bottle. As NAD+ continues to trend for its role in cellular repair and longevity, the gap between marketing and reality becomes even more concerning. Related: Why Top Entrepreneurs Are Swapping Beach Vacations for Longevity Retreats If you're a wellness founder, product integrity is not just a checkbox. It is the heartbeat of your brand. Jeff Byers' company, Momentous, invests in clinical research and testing not because it is required, but because it is what builds lasting trust. Byers told me, "That means showing the science, backing it up with testing, and being radically transparent with our consumers." The next generation of wellness brands will not win on hype. They'll win on data. Consumers are becoming smarter and more demanding, and they want to see the data. SuppCo has already rated over 700 brands and 22,000+ products, and their TrustScore has become remarkably predictive of testing. Now, quality brands are reaching out not just to request a TrustScore, but to get feedback on how to improve their quality practices. When choosing supplements, most people go wrong by treating supplements as if they were all the same. For example, they'll buy the cheapest magnesium without realizing that magnesium oxide has terrible bioavailability compared to magnesium glycinate. Or they'll choose a multivitamin based on how many vitamins are crammed into it, not whether those forms and doses actually work together. Jenna Stangland, co-founder of A4 health and Dietitian for the Minnesota Timberwolves and Minnesota Wild, explains how important it is to ensure that a supplement is tested and validated, as most likely, the dose on the label may not match what is in the bottle and even worse, it could be contaminated. Stangland personally takes NAD+ regularly to support her own energy and help her body adapt to stress and inflammation as she's on airplanes and traveling with teams multiple times per week. Having only tested the creatine and NAD+ categories, SuppCo is just getting started. The company plans to test every major supplement category where there's confusion or questionable quality. This includes protein, magnesium, pre-workouts and nootropics — anywhere consumers are making decisions based on incomplete information, their aim is to bring transparency. Related: Are Your Employees Stressed? You Need to Embrace Transparency. A big milestone they hit recently is the launch of SuppCo Pro, a premium subscription that unlocks deep personalization features. They have received strong user response to their Personal Nutrient Plan, which creates tailored supplement recommendations based on a user's specific goals, as well as their Product Optimizer, which suggests higher-quality, better-value alternatives to what a user is currently taking. This is where the real magic happens, as they can offer truly personalized guidance. I personally appreciate how easy it is to understand their public reports. On the app, you can quickly see whether a product passed or failed, and why. They even launched a browser extension that flags whether the supplement you're browsing has been independently tested. For those of us who care deeply about healthspan, recovery and long-term performance, this kind of transparency is a game-changer.
